Blog

Michael Torres: This review is getting a lot of play

Photo from nature.com

May 22, 2024, 04:28

Michael Torres: This review is getting a lot of play

Michael Torres, PhD in Cancer Bio at UT Southwestern News, shared on X/Twitter:

“Homogeneous multi-payload antibody–drug conjugates | This review is getting a lot of play. Happy to see the ⁦CrossBridge Bio tech flagged as a ‘notable work demonstrating greater benefit compared to co-administration of the single ADC’.

Now all we need to do is leverage the great resources around such as David S. Hong, Martin Dietrich, Paolo Tarantino, MD Anderson Cancer Center and more to get this to patients as soon as we can!

It’s not lost on us that one of the authors is at flagship so wouldn’t be surprised…have they done an ADC co, yet?”

Source: Michael Torres/X

ADC Antibody drug conjugates cancer CrossBridge Bio David S. Hong Homogeneous multi-payload antibody Martin Dietrich MD Anderson Cancer Center Michael Torres OncoDaily Oncology Paolo Tarantino

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage